Strides Pharma Science Limited (STAR.BO)
INR 593.95
(2.87%)
INR 593.95
(2.87%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -706.14 Million INR | 38.39% |
| 2022 | -2.02 Billion INR | 55.97% |
| 2021 | -4.6 Billion INR | -271.44% |
| 2020 | 2.68 Billion INR | 637.66% |
| 2019 | 363.91 Million INR | -88.79% |
| 2018 | 3.24 Billion INR | -51.15% |
| 2017 | 6.64 Billion INR | 66.23% |
| 2016 | 3.99 Billion INR | 268.35% |
| 2015 | 1.08 Billion INR | -87.16% |
| 2014 | 8.44 Billion INR | 552.58% |
| 2013 | -1.86 Billion INR | -122.06% |
| 2012 | 8.46 Billion INR | 276.98% |
| 2011 | 2.24 Billion INR | 83.32% |
| 2010 | 1.22 Billion INR | 11.64% |
| 2009 | 1.09 Billion INR | 1.59% |
| 2008 | 1.07 Billion INR | 315.4% |
| 2007 | -501.21 Million INR | -224.59% |
| 2006 | 402.29 Million INR | -17.16% |
| 2005 | 485.64 Million INR | 10.38% |
| 2004 | 439.98 Million INR | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | 932.32 Million INR | 32.81% |
| 2024 Q1 | 702.02 Million INR | 286.26% |
| 2023 FY | -1.24 Billion INR | 38.39% |
| 2023 Q3 | 496.67 Million INR | 137.81% |
| 2023 Q2 | -1.31 Billion INR | -1746.52% |
| 2023 Q4 | 181.75 Million INR | -63.41% |
| 2023 Q1 | -71.13 Million INR | 25.46% |
| 2022 Q3 | -800.26 Million INR | -450.61% |
| 2022 Q4 | -95.42 Million INR | 88.08% |
| 2022 Q1 | -1.35 Billion INR | -565.08% |
| 2022 FY | -2.02 Billion INR | 55.97% |
| 2022 Q2 | 228.25 Million INR | 116.8% |
| 2021 Q3 | -1.21 Billion INR | 25.15% |
| 2021 Q1 | -2.05 Billion INR | -545.25% |
| 2021 Q2 | -1.62 Billion INR | 20.78% |
| 2021 Q4 | 292.19 Million INR | 124.01% |
| 2021 FY | -4.6 Billion INR | -271.44% |
| 2020 Q3 | 378.47 Million INR | -53.24% |
| 2020 FY | 2.68 Billion INR | 637.66% |
| 2020 Q2 | 809.45 Million INR | -21.84% |
| 2020 Q4 | 460.86 Million INR | 21.77% |
| 2020 Q1 | 1.03 Billion INR | 150.79% |
| 2019 Q2 | 1.42 Billion INR | 3751.98% |
| 2019 Q4 | -2.03 Billion INR | -317.18% |
| 2019 Q1 | 37.05 Million INR | -90.61% |
| 2019 FY | 363.91 Million INR | -88.79% |
| 2019 Q3 | 938.94 Million INR | -34.21% |
| 2018 Q3 | 2.93 Billion INR | 2543.13% |
| 2018 FY | 3.24 Billion INR | -51.15% |
| 2018 Q4 | 394.48 Million INR | -86.56% |
| 2018 Q2 | -120.1 Million INR | -178.65% |
| 2018 Q1 | -43.1 Million INR | -100.75% |
| 2017 Q2 | 85.9 Million INR | 1433.93% |
| 2017 Q3 | 881.1 Million INR | 925.73% |
| 2017 Q4 | 5.76 Billion INR | 554.53% |
| 2017 Q1 | 5.6 Million INR | -99.58% |
| 2017 FY | 6.64 Billion INR | 66.23% |
| 2016 Q2 | 740.9 Million INR | 184.52% |
| 2016 FY | 3.99 Billion INR | 268.35% |
| 2016 Q3 | 1.87 Billion INR | 152.83% |
| 2016 Q4 | 1.31 Billion INR | -29.59% |
| 2016 Q1 | 260.4 Million INR | 67.14% |
| 2015 FY | 1.08 Billion INR | -87.16% |
| 2015 Q2 | 358.1 Million INR | 237.19% |
| 2015 Q4 | 155.8 Million INR | -73.55% |
| 2015 Q3 | 589 Million INR | 64.48% |
| 2015 Q1 | 106.2 Million INR | -6.82% |
| 2014 Q3 | 190.43 Million INR | 144.75% |
| 2014 FY | 8.44 Billion INR | 552.58% |
| 2014 Q2 | -425.57 Million INR | -324.15% |
| 2014 Q1 | 189.85 Million INR | 0.0% |
| 2014 Q4 | 113.97 Million INR | -40.15% |
| 2013 FY | -1.86 Billion INR | -122.06% |
| 2012 FY | 8.46 Billion INR | 276.98% |
| 2011 FY | 2.24 Billion INR | 83.32% |
| 2010 FY | 1.22 Billion INR | 11.64% |
| 2009 FY | 1.09 Billion INR | 1.59% |
| 2008 FY | 1.07 Billion INR | 315.4% |
| 2007 FY | -501.21 Million INR | -224.59% |
| 2006 FY | 402.29 Million INR | -17.16% |
| 2005 FY | 485.64 Million INR | 10.38% |
| 2004 FY | 439.98 Million INR | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Alembic Pharmaceuticals Limited | 6.15 Billion INR | 111.467% |
| Aurobindo Pharma Limited | 31.72 Billion INR | 102.225% |
| Glenmark Life Sciences Limited | 4.7 Billion INR | 114.996% |
| Granules India Limited | 4.05 Billion INR | 117.422% |
| Indoco Remedies Limited | 984.6 Million INR | 171.718% |
| Achyut Healthcare Limited | 5.73 Million INR | 12419.26% |
| Ajanta Pharma Limited | 8.16 Billion INR | 108.652% |
| Alkem Laboratories Limited | 17.95 Billion INR | 103.932% |
| Alpa Laboratories Limited | 167.76 Million INR | 520.91% |
| Brooks Laboratories Limited | -195.91 Million INR | -260.424% |
| AstraZeneca Pharma India Limited | 1.61 Billion INR | 143.721% |
| Bajaj HealthCare Limited | -837.93 Million INR | 15.728% |
| Bliss GVS Pharma Limited | 754.54 Million INR | 193.585% |
| Dr. Reddy's Laboratories Limited | 55.68 Billion INR | 101.268% |
| Eris Lifesciences Limited | 3.91 Billion INR | 118.015% |
| FDC Limited | 3.05 Billion INR | 123.135% |
| Glenmark Pharmaceuticals Limited | -15.01 Billion INR | 95.298% |
| Gufic Biosciences Limited | 861.35 Million INR | 181.98% |
| Ind-Swift Laboratories Limited | 4.2 Billion INR | 116.774% |
| Ipca Laboratories Limited | 5.47 Billion INR | 112.901% |
| Jagsonpal Pharmaceuticals Limited | 224.63 Million INR | 414.357% |
| Krebs Biochemicals & Industries Limited | -197.28 Million INR | -257.931% |
| Lasa Supergenerics Limited | -217.3 Million INR | -224.952% |
| Laurus Labs Limited | 1.6 Billion INR | 143.983% |
| Lupin Limited | 19.14 Billion INR | 103.688% |
| Mankind Pharma Limited | 19.12 Billion INR | 103.691% |
| Medicamen Biotech Limited | 109.31 Million INR | 745.998% |
| Medico Remedies Limited | 82.9 Million INR | 951.705% |
| Megasoft Limited | -127.46 Million INR | -453.983% |
| NATCO Pharma Limited | 13.88 Billion INR | 105.086% |
| Piramal Pharma Limited | 178.2 Million INR | 496.263% |
| RPG Life Sciences Limited | 876.6 Million INR | 180.554% |
| Sigachi Industries Limited | 571.8 Million INR | 223.494% |
| Sun Pharmaceutical Industries Limited | 95.76 Billion INR | 100.737% |
| Suven Pharmaceuticals Limited | 3 Billion INR | 123.516% |
| Syncom Formulations (India) Limited | 253.14 Million INR | 378.95% |
| Unichem Laboratories Limited | -704.74 Million INR | -0.198% |
| Wanbury Limited | 559.56 Million INR | 226.195% |
| Windlas Biotech Limited | 581.87 Million INR | 221.357% |
| ZIM Laboratories Limited | 172.46 Million INR | 509.442% |
| Zydus Lifesciences Limited | 38.59 Billion INR | 101.83% |
| Sun Pharma Advanced Research Company Limited | -3.87 Billion INR | 81.764% |
| Divi's Laboratories Limited | 16 Billion INR | 104.413% |
| Hester Biosciences Limited | 188.89 Million INR | 473.837% |
| Procter & Gamble Health Limited | 2 Billion INR | 135.135% |
| Amrutanjan Health Care Limited | 449.72 Million INR | 257.016% |
| Bal Pharma Limited | 73.92 Million INR | 1055.25% |
| Venus Remedies Limited | 284.9 Million INR | 347.848% |
| Aarti Pharmalabs Limited | 2.16 Billion INR | 132.556% |
| Nectar Lifesciences Limited | 49.95 Million INR | 1513.694% |
| Shilpa Medicare Limited | 318.74 Million INR | 321.54% |
| Aarti Drugs Limited | 1.71 Billion INR | 141.194% |
| IOL Chemicals and Pharmaceuticals Limited | 1.34 Billion INR | 152.528% |
| Suven Life Sciences Limited | -1.05 Billion INR | 32.797% |
| Ind-Swift Limited | 142.31 Million INR | 596.188% |
| Valiant Laboratories Limited | 3.19 Million INR | 22194.493% |
| J. B. Chemicals & Pharmaceuticals Limited | 5.52 Billion INR | 112.778% |
| Solara Active Pharma Sciences Limited | -5.67 Billion INR | 87.555% |
| Themis Medicare Limited | 435.23 Million INR | 262.242% |
| Hikal Limited | 696.02 Million INR | 201.454% |
| Torrent Pharmaceuticals Limited | 16.56 Billion INR | 104.263% |
| Sequent Scientific Limited | -358.69 Million INR | -96.866% |
| Novartis India Limited | 851.9 Million INR | 182.89% |
| Wockhardt Limited | -4.63 Billion INR | 84.749% |
| Jubilant Pharmova Limited | 771 Million INR | 191.588% |
| Biofil Chemicals and Pharmaceuticals Limited | 7.09 Million INR | 10056.853% |
| Neuland Laboratories Limited | 3 Billion INR | 123.532% |
| Morepen Laboratories Limited | 961.59 Million INR | 173.434% |
| Kilitch Drugs (India) Limited | 146.01 Million INR | 583.611% |
| Mangalam Drugs & Organics Limited | -90.71 Million INR | -678.399% |